Tag Archives: paclitaxel

Los DES de última generación presentan mejores resultados en puentes venosos que los DES antiguos y BMS

Drug-Eluting Stents vs. Balloons While Paclitaxel Is in the Eye of the Storm

Drug-Eluting Stents vs. Balloons While Paclitaxel Is in the Eye of the Storm

Even after the US Food and Drug Administration (FDA) issued an alert on paclitaxel devices in patients with femoropopliteal artery disease, which caused the interruption of a few ongoing studies, reality indicates that the efficacy of these devices has been proven and that they are still used. The increased mortality observed in the meta-analysis that

Los balones farmacológicos pasaron la prueba del tiempo en territorio femoropoplíteo

FDA Alert on Drug-Coated Balloons and Stents in Femoropopliteal Artery Disease

The US Food and Drug Administration (FDA) has issued an alert on the potential long-term risk of paclitaxel-coated balloons and paclitaxel-eluting stents in patients with femoropopliteal artery disease. This agency is evaluating signals of increased long-term deaths among patients with femoral or popliteal artery disease treated with paclitaxel-coated devices in a recent study.   In

Efecto a largo plazo de los balones liberadores con bajas dosis de paclitaxel

Long Term Effect of Low Dose Paclitaxel Coated Balloon

The beneficial effect of low dose drug coated balloons with paclitaxel is sustained in time according to this randomized study. In a nutshell, this study has shown a significant statistical difference in favor of paclitaxel coated balloons vs. conventional PCI at 2 years. The safety and efficacy of new generation low dose drug coated balloons

imperial-TCT 2018

TCT 2018 | IMPERIAL: First Study Comparing Drug-Eluting Stents in Patients with Femoropopliteal Disease

The IMPERIAL trial compared the safety and efficacy of a nitinol self-expanding polymer-free placlitaxel-eluting stent (Zilver PTX, Cook Medical, already approved by the US Food and Drug Administration [FDA]) and a nitinol self-expanding polymer-coating placlitaxel-eluting stent (Eluvia, Boston Scientific). This was a single-blind randomized trial in patients with symptomatic intermittent claudication (Rutherford categories 2, 3, or

Los balones farmacológicos pasaron la prueba del tiempo en territorio femoropoplíteo

Pharmacological balloons in femoropopliteal territory passed time testing

Endovascular revascularization has become the main strategy for symptomatic patients with peripheral arterial disease in femoropopliteal territory. Conventional balloon angioplasty is effective in gaining lumen but has a restenosis rate to up 60% at 12 months. Implantation of conventional stents reduced restenosis to almost half, but presented problems such as thrombosis, stent fracture and difficulty

DARE: los balones farmacológicos compiten con los DES para tratar la reestenosis intrastent

DARE: Drug-Coated Balloons Compete with DES for the Treatment of In-Stent Restenosis

Courtesy of the Brazilian Society of Hemodynamics and Interventional Cardiology (SBHCI). The SeQuent Please paclitaxel-coated balloon provides non-inferior angiographic results when compared with the Xience everolimus-eluting stent for the treatment of in-stent restenosis. At 6 months, the minimal lumen diameter was 1.71 mm in the drug-coated balloon arm and 1.74 mm in the Xience arm, a difference that

Resultados a 2 años del balón farmacológico Lutonix sobre la femoral superficial

2 Year Outcomes of Lutonix Drug Coated Balloon in Superficial Femoral Arteries

  There are plenty of clinical studies assessing the use of angioplasty for en la peripheral artery disease with restenosis rates as high as 40% and 60% at 6 and 12 months. Drug coated balloons have significantly raised primary patency, but they have mostly been tested in short lesions with mild calcification and no total occlusions.   This

Zilver-PTX

Zilver PTX: Maintains efficacy in real life most challenging lesions?

Original Title: Zilver PTX Post-Market Surveillance Study of Paclitaxel-Eluting Stents for Treating Femoropopliteal Artery Disease in Japan 12-Month Results. Reference: Hiroyoshi Yokoi et al. J Am Coll Cardiol Intv. 2016;9(3):271-277.   This multicenter prospective study carried out in Japan assessed the paclitaxel eluting stent Zilver PTX in an unselected real world population very different to

Drug-Coated Balloons in Complex Superficial Femoral Artery Lesions

Original Title: Drug-Coated Balloons for Complex Femoropopliteal Lesions2-Year Results of a Real-World Registry. Reference: Andrej Schmidt et al. J Am CollCardiolIntv. 2016;9(7):715-724.   The superiority of drug coated balloons compared to conventional balloons in femoropopliteal lesions have been shown by randomized studies, but only in short and simple lesions. The efficacy of drug coated balloons

DES in critical ischemia caused by infrapopliteal lesions

Original Title: Percutaneous Transluminal Angioplasty and Drug-Eluting Stents for Infrapopliteal Lesions in Critical Limb Ischemia (PADI) Trial. Reference: Marlon I. Spreen et al. Circ Cardiovasc Interv. 2016 Feb;9(2):e002376.   The treatment of infrapopliteal lesions in patients with critical limb ischemia is limited by the high rates of restenosis. The most frequent course of treatment is

Top